8-K Announcements
6Material company update
May 8, 2026·SEC
Material company update
May 6, 2026·SEC
Material company update
Apr 28, 2026·SEC
Allarity Therapeutics, Inc.(ALLR)Earnings, Financials & Key Ratios
ALLR•NASDAQ
$1.30
Price updated Jun 27, 2026
AboutAllarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$320K
- EBITDA-$13M+53.7%
- Net Income-$11M+54.2%
- EPS (Diluted)-0.78+95.1%
- Gross Margin100%
- EBITDA Margin-3943.13%
- Operating Margin-3939.06%
- Net Margin-3509.69%
- ROE-103.8%+80.8%
ALLR Price & Volume
Allarity Therapeutics, Inc. (ALLR) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Challenges Clinical Development Pipeline
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial failure
"Allarity Therapeutics faces a precarious financial outlook characterized by minimal, sporadic revenue and a reliance on external financing to sustain its clinical-stage drug development. While the DRP platform provides a theoretical edge in patient selection, the company's inability to achieve commercial scale, evidenced by a TTM revenue of only $320,000, creates significant binary risk for investors. The firm's long-term viability remains highly uncertain as it continues to navigate deep operating losses and a rapidly eroding equity base."
Verdict Logic
the company's precarious financial position, underscored by a current ratio that has declined to 1.23 and a consistent history of deep net losses, suggests a high probability of further dilutive financing or insolvency risks.
ALLR Growth Metrics
Allarity Therapeutics, Inc. (ALLR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-1.23%
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM51.94%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM94.18%
Return on Capital
10 Years-471.03%
5 Years-873.1%
3 Years-1352.72%
Last Year-116.5%
ALLR Recent Earnings
Allarity Therapeutics, Inc. (ALLR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (60%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.17+22.7%
$0.22
Rev
$25,000+0.0%
$25,000
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.19+13.6%
$0.22
Rev
$320,000+0.0%
$320,000
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.19+17.4%
$0.23
Rev
—
—
Q3 2025
Aug 15, 2025Metric
Actual
Est
EPS
$0.15+28.6%
$0.21
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.17vs $0.22+22.7% | $25,000vs $25,000+0.0% |
| Q2 2026 | Mar 31, 2026 | $0.19vs $0.22+13.6% | $320,000vs $320,000+0.0% |
| Q4 2025 | Nov 14, 2025 | $0.19vs $0.23+17.4% | — |
| Q3 2025 | Aug 15, 2025 | $0.15vs $0.21+28.6% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Allarity Therapeutics, Inc. (ALLR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.30 | $20.68M | -1.67 | — | -3509.69% | -103.8% | — | |
| $4.70 | $190.82M | 3.85 | 36.55% | -19.55% | -3.39% | — | |
| $0.15 | $2.33M | -0.06 | -15.77% | -183.93% | — | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $0.31 | $60.51M | -0.54 | -13.43% | -299.66% | — | — | |
| $2.52 | $8.04M | -0.30 | — | — | -264.79% | — |
Compare ALLR vs Peers
Allarity Therapeutics, Inc. (ALLR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALLR SEC Filings & Documents
Allarity Therapeutics, Inc. (ALLR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ALLR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ALLR Frequently Asked Questions
Allarity Therapeutics, Inc. (ALLR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Allarity Therapeutics, Inc.'s revenue?
Allarity Therapeutics, Inc. (ALLR) reported $0.3M in revenue for fiscal year 2025.
Is ALLR profitable?
Allarity Therapeutics, Inc. (ALLR) reported a net loss of $11.2M for fiscal year 2025.
Dividend & Returns
What is ALLR's return on equity?
Allarity Therapeutics, Inc. (ALLR) has a return on equity (ROE) of -103.8%. Negative ROE indicates the company is unprofitable.
What is Allarity Therapeutics, Inc.'s free cash flow?
Allarity Therapeutics, Inc. (ALLR) had negative free cash flow of $16.7M in fiscal year 2025, likely due to heavy capital investments.